Phase 2 Study to Evaluate Efficacy and Safety of MR13A9 in Hemodialysis Patients with Uremic Pruritus.
Phase of Trial: Phase II
Latest Information Update: 11 Jul 2018
At a glance
- Drugs Difelikefalin (Primary)
- Indications Pruritus
- Focus Therapeutic Use
- Sponsors Maruishi Pharmaceutical
- 11 Jul 2018 According to Cara Therapeutics data from this study were presented at the 2017 American Society of Nephrologys Annual Meeting.
- 01 Nov 2017 Status changed from active, no longer recruiting to completed.
- 19 Sep 2017 Status changed from recruiting to active, no longer recruiting.